-
Cost-Effectiveness Analysis of Fixed-Dose Combination Rosuvastatin and Ezetimibe vs. Simvastatin Plus Ezetimibe for the Treatment of Hypercholesterolemia in Patients at High Risk and Very High Risk of Cardiovascular Disease in Algeria
Sep 9, 2025, 16:22 PM -
Barriers and Facilitators Influencing the Development of Complex Generics: An Exploratory Study
Sep 9, 2025, 16:22 PM -
Cost Impact of the Porcine Urinary Bladder Matrix in Patients With Diabetic Foot Ulcer in the United Kingdom
Sep 9, 2025, 16:22 PM -
Early Impact of the Mazars Review on Reimbursement Timelines in Ireland
Sep 9, 2025, 16:22 PM -
Leveraging AI for Evidence Synthesis: Assessing the Accuracy and Efficiency of AI-Supported Data Extraction and Reporting
Sep 9, 2025, 16:22 PM -
Assessing the Cost-Effectiveness of Lecanemab for Early Alzheimer's Disease Treatment: A Swiss Perspective
Sep 9, 2025, 16:22 PM -
Impact of Transfusion-Dependent Thalassemia on Adult Patients’ Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates
Sep 9, 2025, 16:22 PM -
Postherpetic Neuralgia Occurrence and Herpes Zoster Recurrence in Immunocompromised Adults Aged 18 Years or Older in England: A Large Retrospective Cohort Study (Clinical Practice Research Datalink 2012-2019)
Sep 9, 2025, 16:22 PM -
Exploring Methodologies for Defining and Modeling Cure in Melanoma: Impacts on Estimating Cure Metrics
Sep 9, 2025, 16:22 PM -
Harmonization or Hindrance? A Strategic Analysis of Divergent National Requirements Under the EU Joint Clinical Assessment
Sep 9, 2025, 16:22 PM -
Targeted Review of mITT vs. ITT Data in CAR-T Submissions
Sep 9, 2025, 16:22 PM -
Environmental Sustainability in HTA: To What Extent Are HTA Bodies Considering Environmental Considerations in Their Decision Making?
Sep 9, 2025, 16:22 PM -
Utilization of Glucagon-Like Peptide-1 Receptor Agonists in the Irish Healthcare System
Sep 9, 2025, 16:22 PM -
Analysis of Clinical and Economic Evidence Focused on RWE in Medicare Drug Price Negotiations: Sacubitril/Valsartan, Rivaroxaban, and Apixaban
Sep 9, 2025, 16:22 PM -
Organizational Support in Adopting New Treatments for Generalized Myasthenia Gravis
Sep 9, 2025, 16:22 PM -
A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Modeling Based on a Clinical Trial Re-analysis Using Multimodal Machine Artificial Intelligence Methodology: Predicting Which Patients May Benefit Most From the Addition of Tremelimumab to Durvalumab Plus Chemotherapy in First-Line...
Sep 9, 2025, 16:22 PM -
What Did Time Reveal? Evaluating the Accuracy of Parametric Model Predictions Against Long-Term Observed Data for Larotrectinib
Sep 9, 2025, 16:22 PM -
Digital Therapeutics in Europe: A Structured Review of Reimbursement and Access Pathways
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Subcutaneous Ocrelizumab for Relapsing Multiple Sclerosis in Italy: A Hospital Perspective
Sep 9, 2025, 16:22 PM
